Refractory Malignant Solid Neoplasm Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
Recruiting
  • Recurrent Alveolar Rhabdomyosarcoma
  • +7 more
  • Birmingham, Alabama
  • +17 more
2022-04-07
Apr 7, 2022
N
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Recruiting
  • Advanced Malignant Solid Neoplasm
  • +49 more
  • Birmingham, Alabama
  • +1423 more
2022-04-06
Apr 6, 2022
N
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +35 more
  • Birmingham, Alabama
  • +108 more
2022-04-06
Apr 6, 2022
N
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +40 more
  • Birmingham, Alabama
  • +117 more
2022-04-06
Apr 6, 2022
N
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
Recruiting
  • Constitutional Mismatch Repair Deficiency Syndrome
  • +11 more
  • Biospecimen Collection
  • +2 more
  • Palo Alto, California
  • +8 more
2022-04-05
Apr 5, 2022
N
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Active, not recruiting
  • Metastatic Melanoma
  • +22 more
  • Ipilimumab
  • +3 more
  • Birmingham, Alabama
  • +24 more
2022-04-05
Apr 5, 2022
N
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Copanlisib Hydrochloride
  • +2 more
  • Boston, Massachusetts
  • +5 more
2022-04-05
Apr 5, 2022
N
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
Recruiting
  • Malignant Solid Neoplasm
  • +2 more
  • Birmingham, Alabama
  • +11 more
2022-04-02
Apr 2, 2022
N
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
Suspended
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-31
Mar 31, 2022
N
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Recruiting
  • Locally Advanced Cholangiocarcinoma
  • +28 more
  • Sacramento, California
  • +6 more
2022-03-30
Mar 30, 2022
N
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Recruiting
  • Metastatic Colorectal Carcinoma
  • +29 more
  • Los Angeles, California
  • +22 more
2022-03-29
Mar 29, 2022
N
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas
Not yet recruiting
  • Advanced Lymphoma
  • +13 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +2 more
  • (no location specified)
2022-03-30
Mar 30, 2022
N
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
Recruiting
  • Recurrent Ependymoma
  • +32 more
  • Birmingham, Alabama
  • +170 more
2022-03-25
Mar 25, 2022
M
Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors
Active, not recruiting
  • Recurrent Malignant Solid Neoplasm
  • Refractory Malignant Solid Neoplasm
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-24
Mar 24, 2022
N
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Recruiting
  • Advanced Malignant Solid Neoplasm
  • +44 more
  • Biopsy
  • +16 more
  • Birmingham, Alabama
  • +163 more
2022-03-24
Mar 24, 2022
N
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +35 more
  • Birmingham, Alabama
  • +113 more
2022-03-23
Mar 23, 2022
N
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +22 more
  • Birmingham, Alabama
  • +116 more
2022-03-23
Mar 23, 2022
C
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Recruiting
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • +10 more
  • FACT Complex-targeting Curaxin CBL0137
  • Birmingham, Alabama
  • +13 more
2022-03-22
Mar 22, 2022
C
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Active, not recruiting
  • Recurrent Lymphoma
  • +5 more
  • Birmingham, Alabama
  • +19 more
2022-03-23
Mar 23, 2022
N
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
Suspended
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +37 more
  • Birmingham, Alabama
  • +169 more
2022-03-19
Mar 19, 2022
N
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
Active, not recruiting
  • Metastatic Melanoma
  • +3 more
  • Jacksonville, Florida
  • +1 more
2022-03-15
Mar 15, 2022
N
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
Suspended
  • Advanced Malignant Solid Neoplasm
  • Refractory Malignant Solid Neoplasm
  • Duarte, California
  • +8 more
2022-03-15
Mar 15, 2022
N
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Suspended
  • Advanced Malignant Solid Neoplasm
  • +26 more
  • Birmingham, Alabama
  • +115 more
2022-03-09
Mar 9, 2022
N
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Recruiting
  • Advanced Malignant Solid Neoplasm
  • +30 more
  • Larotrectinib Sulfate
  • Birmingham, Alabama
  • +121 more
2022-03-09
Mar 9, 2022
N
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Suspended
  • Advanced Malignant Solid Neoplasm
  • +32 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Birmingham, Alabama
  • +121 more
2022-03-08
Mar 8, 2022